Navigation Links
Abbott Announces Positive Six-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent

Abbott's Bioabsorbable Stent Technology Holds Promise as Future-Generation Treatment Option for Physicians Treating Patients with Coronary Artery Disease

ABBOTT PARK, Ill., March 24, 2007 /PRNewswire-FirstCall/ -- Abbott today announced positive results from ABSORB, the world's first clinical trial evaluating the overall safety and performance of a fully bioabsorbable drug- eluting stent platform for the treatment of coronary artery disease. Six- month results from the first 30 patients in the trial, presented at the 56th Annual of Cardiology Scientific Session in New Orleans, demonstrated no stent thrombosis and a low (3.3 percent) hierarchical rate of ischemia-driven Major Adverse Cardiac Events (MACE), such as heart attack or repeat intervention.

"The encouraging results from the first 30 patients of ABSORB suggest that drug-eluting bioabsorbable stent technologies may be a promising future therapy option for physicians treating patients with heart disease," said Patrick W. Serruys, M.D., Ph.D., professor of interventional cardiology at the Thoraxcentre, Erasmus University Hospital, Rotterdam, who is co-principal investigator of the study. "A drug eluting stent that would eventually disappear after restoring blood flow is an exciting concept that we look forward to further exploring."

The single MACE event reported was a non-Q-wave myocardial infarction. The same patient underwent a repeat intervention that occurred at the site of the original procedure, resulting in an overall target lesion revascularization rate of 3.3 percent. The trial results confirmed that the treatment effect of everolimus in the bioabsorbable stent is similar to that observed in Abbott's studies of metallic drug-eluting stents, with everolimus actively inhibiting tissue growth into the artery. The rate of device success (successful placement of the bioabsorbable stent at the site of the lesion) was 93.5 percent.

Abbott's everolimus-eluting bioabsorbable stent is made of polylactic acid, a proven biocompatible material that is commonly used in medical implants such as dissolvable sutures. As with a metallic stent, the bioabsorbable stent is designed to restore blood flow by propping the vessel open, providing support until the blood vessel heals. Unlike a metallic stent, a bioabsorbable stent is designed to be slowly metabolized by the body and completely absorbed over time.

"Based on these encouraging safety results, Abbott will continue to advance this technology by enrolling the next cohort of patients in the ABSORB study in Europe and New Zealand," said John M. Capek, Ph.D., senior vice president, Abbott Vascular. "The next phase of the ABSORB study will utilize a next-generation bioabsorbable everolimus-eluting stent that incorporates several advancements designed to improve strength and deliverability."

About the ABSORB Trial

The ABSORB trial is a prospective, non-randomized (open label) study designed to enroll up to 60 patients in Belgium, Denmark, France, New Zealand, Poland and The Netherlands. Key endpoints of the study include assessments of safety -- MACE and stent thrombosis (blood clot formation) rates -- at 30, 180 and 270 days, with an annual follow-up for up to five years, and successful deployment of the bioabsorbable drug-eluting stent. Other key endpoints of the study include follow-up measurements assessed by angiography, IVUS, and state- of-the-art imaging modalities at 180 days and two years, as well as a new noninvasive technique in a subset of patients at 18 months. The co-principal investigator of the study is John Ormiston, M.D., of Mercy Hospital in Auckland, New Zealand.

For images of Abbott's bioabsorbable stent and other information, please visit the company's online ACC newsroom at http://www.abbottvascular.com/ACCpresskit .

About Abbot t Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products that are recognized internationally for their safety and effectiveness in treating patients with vascular disease.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com .

CONTACT: Media, Karin Bauer Aranaz, +1-415-859-3414, , Nicole Osmer, +1-650-454-0504, , or Financial, Tina Ventura, +1-847-772-5006, , all of Abbott karin.baueraranaz@av.abbott.com nicole.osmer@av.abbott.com tina.ventura@abbott.com

Web site: http://www.abbott.com/

Ticker Symbol: (:ABT)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
4. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
5. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
6. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
7. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
8. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
9. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2017)... 2017  Thornhill Research Inc. ( Toronto, ... $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract by the ... Corporation (CCC) ( Ottawa, Ontario, Canada ... general anesthesia to patients requiring emergency medical procedures ... Marine Corps have been a longtime partner with ...
(Date:5/10/2017)... GLEN BURNIE, Md. , May 10, 2017 /PRNewswire/ ... and retention solutions for the clinical research industry, is ... website, www.CSSiEnroll.com . The new website features both ... better overall user experience and enhances the company,s already ... in the industry. "After many months ...
(Date:5/8/2017)... , May 8, 2017 MACRA replaces ... from fee for service reimbursement. Black Book Research crowdsource-surveyed ... 1.       The Market for MIPS Compliance Technology ... of physician practices with 3 or more clinicians seek ... by Q4. "Given the magnitude of the changes, the ...
Breaking Medicine Technology:
(Date:5/24/2017)... , ... May 24, 2017 , ... ... medical image management and interpretation, has received U.S. Food and Drug Administration (FDA) ... is a web-based, scalable and secure cloud platform for medical image management. At ...
(Date:5/24/2017)... ... May 24, 2017 , ... STATEMENT ... is vehemently opposed to Donald Trump’s budget, “A New Foundation for American Greatness—President's ... fear, demonizes the poor, marginalizes underserved populations, undermines productivity, and destroys the social ...
(Date:5/24/2017)... ... May 24, 2017 , ... Medic CE , a Career Step ... Pediatric Septic Shock” hosted by the Journal of Emergency Medical Services (JEMS). The free ... will be presented by Captain Rommie Duckworth, LP, a career fire captain as well ...
(Date:5/24/2017)... ... ... Lowe is a sought after actor, and also serves as the host of the ... all aspects of life, and a new segment is being developed on podiatry, which ... is essential to people’s overall well-being, and if viewers have feet problems, they may ...
(Date:5/24/2017)... ... 24, 2017 , ... Dymedix® Diagnostics, Inc., the ... it had completed the first phase of building a global distribution network. To ... world (ROW) authorized dealers specializing in polysomnography accessories. The company plans to ...
Breaking Medicine News(10 mins):